12,372 trials
Asthma
Primary: Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3 — 2.68; 1.63 score on a scale — p=0.385
Liver Cirrhosis
Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
Trachomatous Trichiasis (TT) · Eye Diseases · Eyelid Diseases
Primary: Incidence of Postoperative TT by One Year, as Determined by Trained Study Team Members — 218; 213; 32; 36 Study eyes — p=0.97
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events — 46; 8; 6; 5 Participants
Alcohol Use Disorder
Primary: Cue-induced Alcohol Cravings Using the Alcohol Urge Questionnaire — -22.67; -23.67 score on a scale
Sedation
Primary: The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs…
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Laboratory Test Abnormalities — 294 Participants
Chronic Heart Failure
Primary: Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE) — 29.70; 27.53…
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) — 31.50; 63.20 percentage of participants — p=<0.0001
FSGS
Primary: Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria — 14 Participants
Adult Onset Still's Disease
Primary: Percentage of Participants Who Achieved Adapted American College of Rheumatology (ACR) 30 Response at Week 8 — 50.0 Percentage of participants
Anterior Cruciate Ligament Injury
Primary: Pain Levels Using the Visual Analog Scale — 2.5; 4.06 score on a scale (0-10 on VAS pain scale — p=<0.001
Asthma
Primary: Change From Baseline to the Average of the Entire Treatment Period Reported, in the Average Pre-dose Morning Peak Expiratory Flow (PEF) — 16.45; -3.63 L/min — p=<0.001
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points